145 related articles for article (PubMed ID: 17900227)
1. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.
Kim CY; Hong S; Seong GJ
J Ocul Pharmacol Ther; 2007 Oct; 23(5):481-6. PubMed ID: 17900227
[TBL] [Abstract][Full Text] [Related]
2. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
3. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Sharpe ED; Day DG; Beischel CJ; Rhodes JS; Stewart JA; Stewart WC
Br J Ophthalmol; 2004 Jul; 88(7):953-6. PubMed ID: 15205246
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
7. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
[TBL] [Abstract][Full Text] [Related]
8. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
9. Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering.
Simmons ST; Earl ML;
Ophthalmology; 2002 Feb; 109(2):307-14; discussion 314-5. PubMed ID: 11825814
[TBL] [Abstract][Full Text] [Related]
10. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
11. Ocular hypotensive efficacy of brimonidine 0.15% as adjunctive therapy with latanoprost 0.005% in patients with open-angle glaucoma or ocular hypertension.
Mundorf T; Noecker RJ; Earl M
Adv Ther; 2007; 24(2):302-9. PubMed ID: 17565920
[TBL] [Abstract][Full Text] [Related]
12. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
13. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure.
Yüksel N; Karabaş L; Altintaş O; Yildirim Y; Cağlar Y
Ophthalmologica; 2002; 216(1):45-9. PubMed ID: 11901288
[TBL] [Abstract][Full Text] [Related]
15. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
16. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1.
Whitson JT; Ochsner KI; Moster MR; Sullivan EK; Andrew RM; Silver LH; Wells DT; James JE; Bosworth CF; Dickerson JE; Landry TA; Bergamini MV;
Ophthalmology; 2006 Aug; 113(8):1333-9. PubMed ID: 16877072
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
18. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
[TBL] [Abstract][Full Text] [Related]
19. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
[TBL] [Abstract][Full Text] [Related]
20. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
